Inhibikase Therapeutics Statistics
Share Statistics
Inhibikase Therapeutics has 74.34M
shares outstanding. The number of shares has increased by 861.21%
in one year.
| Shares Outstanding | 74.34M |
| Shares Change (YoY) | 861.21% |
| Shares Change (QoQ) | 3.23% |
| Owned by Institutions (%) | 99.99% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 2,729 |
| FTD / Avg. Volume | 2.09% |
Short Selling Information
The latest short interest is 1.38M, so 1.86% of the outstanding
shares have been sold short.
| Short Interest | 1.38M |
| Short % of Shares Out | 1.86% |
| Short % of Float | 4.6% |
| Short Ratio (days to cover) | 12.57 |
Valuation Ratios
The PE ratio is -2.8 and the forward
PE ratio is -4.28.
Inhibikase Therapeutics's PEG ratio is
0.04.
| PE Ratio | -2.8 |
| Forward PE | -4.28 |
| PS Ratio | 0 |
| Forward PS | 0.5 |
| PB Ratio | 0.81 |
| P/FCF Ratio | -4.02 |
| PEG Ratio | 0.04 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Inhibikase Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 26.37,
with a Debt / Equity ratio of 0.
| Current Ratio | 26.37 |
| Quick Ratio | 26.37 |
| Debt / Equity | 0 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.01 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | $-1,834,659.07 |
| Employee Count | 15 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by 9.24% in the
last 52 weeks. The beta is 1.01, so Inhibikase Therapeutics's
price volatility has been higher than the market average.
| Beta | 1.01 |
| 52-Week Price Change | 9.24% |
| 50-Day Moving Average | 2.07 |
| 200-Day Moving Average | 2.19 |
| Relative Strength Index (RSI) | 49.69 |
| Average Volume (20 Days) | 130,819 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -28.59M |
| Net Income | -27.52M |
| EBITDA | -27.49M |
| EBIT | -27.52M |
| Earnings Per Share (EPS) | -1.16 |
Full Income StatementBalance Sheet
The company has 56.49M in cash and 110.52K in
debt, giving a net cash position of 56.38M.
| Cash & Cash Equivalents | 56.49M |
| Total Debt | 110.52K |
| Net Cash | 56.38M |
| Retained Earnings | -94.42M |
| Total Assets | 94.28M |
| Working Capital | 85.61M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -19.15M
and capital expenditures 0, giving a free cash flow of -19.15M.
| Operating Cash Flow | -19.15M |
| Capital Expenditures | n/a |
| Free Cash Flow | -19.15M |
| FCF Per Share | -0.81 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
